Nyxoah (NYXH) - Net Assets
Based on the latest financial reports, Nyxoah (NYXH) has net assets worth €50.95 Million EUR (≈ $59.57 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€93.60 Million ≈ $109.43 Million USD) and total liabilities (€42.65 Million ≈ $49.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Nyxoah to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €50.95 Million |
| % of Total Assets | 54.44% |
| Annual Growth Rate | 58.39% |
| 5-Year Change | 16.53% |
| 10-Year Change | N/A |
| Growth Volatility | 877.2 |
Nyxoah - Net Assets Trend (2017–2024)
This chart illustrates how Nyxoah's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Nyxoah.
Annual Net Assets for Nyxoah (2017–2024)
The table below shows the annual net assets of Nyxoah from 2017 to 2024. Also explore Nyxoah net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €113.25 Million ≈ $132.41 Million |
+15.54% |
| 2023-12-31 | €98.02 Million ≈ $114.60 Million |
-18.53% |
| 2022-12-31 | €120.32 Million ≈ $140.67 Million |
-19.04% |
| 2021-12-31 | €148.62 Million ≈ $173.75 Million |
+52.92% |
| 2020-12-31 | €97.19 Million ≈ $113.63 Million |
+2517.56% |
| 2019-12-31 | €3.71 Million ≈ $4.34 Million |
-64.48% |
| 2018-12-31 | €10.45 Million ≈ $12.22 Million |
+130.93% |
| 2017-12-31 | €4.53 Million ≈ $5.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nyxoah's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18700000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €330.99 Million | 292.25% |
| Total Equity | €113.25 Million | 100.00% |
Nyxoah Competitors by Market Cap
The table below lists competitors of Nyxoah ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gold Terra Resource Corp
V:YGT
|
$68.92 Million |
|
Namib Minerals Ordinary Shares
NASDAQ:NAMM
|
$68.92 Million |
|
Rorze Systems Corporation
KQ:071280
|
$68.94 Million |
|
Harboes Bryggeri A/S
CO:HARB-B
|
$68.95 Million |
|
Abionyx Pharma SA
PA:ABNX
|
$68.88 Million |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
$68.86 Million |
|
Maan Aluminium Limited
NSE:MAANALU
|
$68.85 Million |
|
SLP Resources Bhd
KLSE:7248
|
$68.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nyxoah's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 98,022,000 to 113,254,000, a change of 15,232,000 (15.5%).
- Net loss of 59,236,000 reduced equity.
- New share issuances of 69,722,000 increased equity.
- Other factors increased equity by 4,746,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-59.24 Million | -52.3% |
| Share Issuances | €69.72 Million | +61.56% |
| Other Changes | €4.75 Million | +4.19% |
| Total Change | €- | 15.54% |
Book Value vs Market Value Analysis
This analysis compares Nyxoah's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.45x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.32x to 0.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.22 | €1.37 | x |
| 2018-12-31 | €0.50 | €1.37 | x |
| 2019-12-31 | €0.18 | €1.37 | x |
| 2020-12-31 | €4.40 | €1.37 | x |
| 2021-12-31 | €5.77 | €1.37 | x |
| 2022-12-31 | €4.66 | €1.37 | x |
| 2023-12-31 | €3.42 | €1.37 | x |
| 2024-12-31 | €3.03 | €1.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nyxoah utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1310.24%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.40x
- Recent ROE (-52.30%) is above the historical average (-83.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -229.09% | 0.00% | 0.00x | 2.46x | €-10.82 Million |
| 2018 | -86.85% | 0.00% | 0.00x | 1.72x | €-10.12 Million |
| 2019 | -195.39% | 0.00% | 0.00x | 4.09x | €-7.63 Million |
| 2020 | -12.60% | -17746.38% | 0.00x | 1.17x | €-21.96 Million |
| 2021 | -18.58% | -3241.67% | 0.00x | 1.15x | €-42.48 Million |
| 2022 | -25.95% | -1012.48% | 0.02x | 1.21x | €-43.26 Million |
| 2023 | -44.08% | -993.84% | 0.04x | 1.27x | €-53.01 Million |
| 2024 | -52.30% | -1310.24% | 0.03x | 1.40x | €-70.56 Million |
Industry Comparison
This section compares Nyxoah's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
No peer company data available for comparison.
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgi… Read more